Teva Pharmaceutical Industries (NYSE: TEVA – Get Note) was downgraded by analysts at Piper Sandler from a “neutral” rating to an “underweight” rating in a note released Wednesday to investors, reports The Fly.
A number of other analysts have also weighed in on TEVA recently. StockNews.com moved shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a Tuesday, April 5 research report. Barclays upgraded shares of Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and raised its target price for the company from $11.00 to $13.00 in a report on Tuesday 5 april. Zacks Investment Research moved shares of Teva Pharmaceutical Industries from a ‘sell’ rating to a ‘hold’ rating and set a price target of $11.00 on the stock in a Tuesday, April 12 research report . Sanford C. Bernstein upgraded Teva Pharmaceutical Industries from a “market performer” rating to an “outperformer” rating and set a price target of $11.00 on the stock in a Friday 25 research note. March. Finally, Argus upgraded Teva Pharmaceutical Industries from a “buy” to a “hold” rating in a Thursday, January 27 research note. One equity research analyst gave the stock a sell rating, five gave the stock a hold rating and three gave the stock a buy rating. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $11.83.
NYSE TEVA shares opened at $8.60 on Wednesday. The company has a 50-day moving average price of $8.75 and a two-hundred-day moving average price of $8.74. The stock has a market capitalization of $9.49 billion, a P/E ratio of 22.63, a price-to-earnings growth ratio of 0.98 and a beta of 1.17. Teva Pharmaceutical Industries has a 52-week low of $7.24 and a 52-week high of $11.55. The company has a debt ratio of 1.92, a quick ratio of 0.79 and a current ratio of 1.14.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last released quarterly earnings data on Tuesday, May 3. The company reported earnings per share of $0.55 for the quarter, hitting the consensus estimate of $0.55. The company posted revenue of $3.66 billion for the quarter, versus $3.75 billion expected by analysts. Teva Pharmaceutical Industries achieved a net margin of 2.63% and a return on equity of 24.40%. Teva Pharmaceutical Industries’ revenue for the quarter was down 8.1% year over year. In the same quarter a year earlier, the company posted earnings per share of $0.60. Analysts expect Teva Pharmaceutical Industries to post earnings per share of 2.44 for the current fiscal year.
In other news, Executive Vice President Eli Shani sold 5,311 shares in a trade that took place on Monday, February 28. The stock was sold at an average price of $8.14, for a total value of $43,231.54. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC’s website. Additionally, Vice Chairman David Matthew Stark sold 6,452 shares of the company in a transaction that took place on Monday, February 28. The shares were sold at an average price of $8.14, for a total value of $52,519.28. The disclosure of this sale can be found here. In the past ninety days, insiders have sold 22,011 shares of the company worth $188,598. 0.74% of the shares are held by insiders of the company.
A number of large investors have recently changed their holdings in TEVA. Fieldpoint Private Securities LLC increased its position in Teva Pharmaceutical Industries shares by 100,000.0% during the first quarter. Fieldpoint Private Securities LLC now owns 3,003 shares of the company worth $28,000 after purchasing an additional 3,000 shares in the last quarter. Koshinski Asset Management Inc. increased its stake in Teva Pharmaceutical Industries by 61.6% during the fourth quarter. Koshinski Asset Management Inc. now owns 3,934 shares of the company worth $32,000 after acquiring an additional 1,500 shares during the period. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries by 932.2% in the fourth quarter. Kistler Tiffany Companies LLC now owns 4,139 shares of the company worth $33,000 after purchasing 3,738 additional shares in the last quarter. Huntington National Bank increased its stake in Teva Pharmaceutical Industries by 115.7% in the fourth quarter. National Bank Huntington now owns 4,850 shares of the company valued at $38,000 after purchasing an additional 2,601 shares during the period. Finally, Future Financial Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during Q4 for $49,000. Institutional investors and hedge funds hold 45.79% of the company’s shares.
About Teva Pharmaceutical Industries (Get a rating)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generic drugs, specialty drugs and biopharmaceuticals in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Teva Pharmaceutical Industries right now?
Before you consider Teva Pharmaceutical Industries, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Teva Pharmaceutical Industries was not on the list.
While Teva Pharmaceutical Industries currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here